1. Frequency of personalized treatment initiation (Time Frame - At 1 year from date of study inclusion): Frequency of personalized treatment initiation
2. Frequency of molecularly stratified treatment options (Time Frame - At 1 year from date of study inclusion): Number of molecularly stratified treatment options per patient
Secondary outcome:
1. Progression free survival (Time Frame - Assessed up to 100 months): From date of study inclusion until the date of first documented progression or date of death from any cause, whichever came first
2. PFS-ratio (Time Frame - Assessed up to 100 months): Ratio of progression-free survival with molecularly matched therapy to progression-free survival with previous treatment line
3. objective response rate (Time Frame - 1 year after study inclusion): Best radiographic response as assessed by the investigator
4. frequency of interventional study inclusion (Time Frame - At 1 year after study inclusion): Number of participants with inclusion in interventional clinical trial
5. frequency of re-diagnosis (Time Frame - At 1 year after study inclusion): Number of participants with a change in diagnosis a
6. frequency of recommendation of genetic counselling (Time Frame - At 1 year after study inclusion): Number of participants with a recommendation for genetic counselling
7. frequency of pharmacogenomic findings (Time Frame - At 1 year after study inclusion): Number of participants with a recommendation for pharmacongenomic considerations a
8. frequency and type of resistance mutations (Time Frame - At 1 year after study inclusion): Number of molecular alterations predicting resistance to molecularly matched therapy a
9. overall survival (Time Frame - Assessed up to 100 months): From date of study inclusion until the date of death from any cause, whichever came first
10. Evidence level of molecularly stratified treatment options (Time Frame - At 1 year from study inclusion): Frequency of evidence levels (according to NCT evidence levels) of molecularly stratified treatment options
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Prospective Observational Study of a Precision Medicine Approach in Patients With Advanced Cancer"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!
